E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Spinal cord injury (SCI) |
Lesión de médula espinal (LME) |
|
E.1.1.1 | Medical condition in easily understood language |
Spinal cord injury (SCI) |
Lesión de médula espinal (LME) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041552 |
E.1.2 | Term | Spinal cord injury |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety and efficacy of elezanumab in subjects with acute traumatic cervical SCI. |
Evaluar la seguridad y la eficacia de elezanumab en sujetos con LME cervical traumática aguda |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Subjects or their legally authorized representative must voluntarily provide informed consent prior to the initiation of any study-specific procedure in a form approved by an independent ethics committee (IEC)/institutional review board (IRB). In the absence of subject's ability to provide informed consent, informed consent must be given by a person who has the legal right to act on behalf of the subject in accordance with local laws. - Adult male or female, between 18 and 70 years of age, inclusive. - Acute traumatic cervical SCI, motor level of injury of C4, C5, C6, or C7 (cervical lesion as defined by first ISNCSCI) with no damage to cord in thoracic (T2 and beyond) and lumbar regions that, in the investigator's opinion, would significantly limit recovery. - Maximum screening UEMS of 32. - AIS grade A or B (2019 criteria) at Screening. - Able to initiate study drug administration within 24 hours of injury. |
- Los sujetos o su representante legalmente autorizado deben proporcionar voluntariamente el consentimiento informado antes de iniciar cualquier procedimiento específico del estudio, que esté aprobado por un comité de ética independiente (CEI)/junta de revisión institucional. En ausencia de la capacidad del sujeto para proporcionar el consentimiento informado, este debe ser proporcionado por una persona que tenga el derecho legal de actuar en nombre del sujeto de acuerdo con las leyes locales. - Hombres o mujeres adultos, entre 18 y 70 años, inclusive. - LME cervical traumática aguda, lesión motora a nivel de C4, C5, C6 o C7 (lesión cervical definida por la primera clasificación neurológica de estándar internacional para LME (ISNCSCI)) sin daño al cordón en las regiones torácica (T2 y más allá) y lumbar que, en opinión del investigador, limiten significativamente la recuperación. - Máxima puntuación motora de las extremidades superiores (UEMS, Upper Extremity Motor Score) de 32 en el screening. - Grados A o B en la escala de evaluación de la discapacidad de la asociación estadounidense de lesiones de la columna (AIS, ASIA Impairment Scale). - Sujetos capaces de iniciar la administración del fármaco del estudio en las 24 horas posteriores a la lesión. |
|
E.4 | Principal exclusion criteria |
- No absence of complete spinal cord transection, as demonstrated by MRI evidence of cord continuity at site of lesion confirmed by neuroradiologist. - Significant concomitant head injury with a clinically significant abnormality on a head computed tomography (CT). CT required only for subjects suspected to have a brain injury at the discretion of the investigator. - Must have 1 or more upper extremity muscle groups untestable (e.g., immobilized or restricted by a cast) during the screening ISNCSCI examination. - Known history prior to randomization of clinically significant medical or surgical conditions (other than current acute SCI) or any other reason, including any physical, psychological, or psychiatric condition that in the opinion of the Investigator would compromise the safety or interfere with the subject's participation in this study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study, including history of or abnormal screening lab or imaging results that, in the opinion of the investigator, are indicative of any irreparable cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease that would preclude administration of elezanumab. - Known receipt of any other investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study. - Female who is pregnant, breastfeeding, or considering becoming pregnant during the study or for within 39 weeks (5 half-lives) after the last dose of study drug. |
- Ausencia completa de transección de la médula espinal, demostrada la continuidad de la médula en una resonancia magnética de la lesión y confirmada por el neuro-radiólogo. - Lesión en la cabeza significativa y concomitante con una anormalidad clínicamente significativa en una tomografía computarizada (TAC). El TAC se requiere solo para sujetos sospechosos de tener una lesión cerebral a discreción del investigador. - Debe tener 1 o más grupos musculares de las extremidades superiores inestables (por ejemplo, inmovilizados o restringidos por un yeso) durante el examen de ISNCSCI del screening. - Historial conocido antes de la aleatorización de afecciones médicas o quirúrgicas clínicamente significativas (que no sean las LME agudas actuales) o por cualquier otro motivo, incluida cualquier condición física, psicológica o psiquiátrica que, en opinión del investigador, comprometería la seguridad o interferiría con la participación del sujeto en este estudio, o convertiría al sujeto en un candidato inadecuado para recibir el fármaco del estudio, o lo pondría en riesgo al participar en el estudio, incluyendo antecedentes o resultados anormales en análisis de laboratorio o imágenes que, en opinión del investigador, son indicativo de cualquier enfermedad cardíaca, endocrina, hematológica, hepática, inmunológica, infecciosa, metabólica, urológica, pulmonar, gastrointestinal, dermatológica, psiquiátrica, renal, neurológica y/u otra enfermedad grave que impida la administración de elezanumab. - Que el sujeto haya recibido cualquier otro producto en investigación en los 30 días o 5 semividas del medicamento (lo que sea más largo) antes de la primera dosis del medicamento del estudio o que esté actualmente inscrito en otro estudio clínico. - Mujer que está embarazada, durante la lactancia o considerando quedarse embarazada durante el estudio o dentro de las 39 semanas (5 semividas) después de la última dosis del fármaco del estudio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the Upper Extremity Motor Score (UEMS), a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI, 2019 criteria) during the Treatment Period. |
El criterio de valoración principal es la UEMS, un punto de los criterios ISNCSCI, durante el período de tratamiento. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
UEMS scores between treatment and placebo. |
Puntuación UEMS entre el tratamiento y el placebo |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are: - Spinal Cord Independence Measures (SCIM III) self-care score, - UEMS change from Baseline |
Los criterios de valoración secundarios son: - Puntuación de autocuidado en las medidas de independencia de la médula espinal (SCIM III, Spinal Chord Independence Measures) - Cambios en la UEMS desde la visita basal |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- SCIM-III is over the duration of the study - UEMS change from baseline at week 52 |
- SCIM-III: durante el estudio - UEMS: cambio desde la visita basal hasta la semana 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
New Zealand |
Spain |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |